Cargando…
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184703/ https://www.ncbi.nlm.nih.gov/pubmed/32340605 http://dx.doi.org/10.1186/s12943-020-01197-3 |
_version_ | 1783526635816878080 |
---|---|
author | Lu, Yuanjun Chan, Yau-Tuen Tan, Hor-Yue Li, Sha Wang, Ning Feng, Yibin |
author_facet | Lu, Yuanjun Chan, Yau-Tuen Tan, Hor-Yue Li, Sha Wang, Ning Feng, Yibin |
author_sort | Lu, Yuanjun |
collection | PubMed |
description | Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response. |
format | Online Article Text |
id | pubmed-7184703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71847032020-04-30 Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy Lu, Yuanjun Chan, Yau-Tuen Tan, Hor-Yue Li, Sha Wang, Ning Feng, Yibin Mol Cancer Review Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response. BioMed Central 2020-04-27 /pmc/articles/PMC7184703/ /pubmed/32340605 http://dx.doi.org/10.1186/s12943-020-01197-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Lu, Yuanjun Chan, Yau-Tuen Tan, Hor-Yue Li, Sha Wang, Ning Feng, Yibin Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title_full | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title_fullStr | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title_full_unstemmed | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title_short | Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
title_sort | epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184703/ https://www.ncbi.nlm.nih.gov/pubmed/32340605 http://dx.doi.org/10.1186/s12943-020-01197-3 |
work_keys_str_mv | AT luyuanjun epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy AT chanyautuen epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy AT tanhoryue epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy AT lisha epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy AT wangning epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy AT fengyibin epigeneticregulationinhumancancerthepotentialroleofepidrugincancertherapy |